A dominant negative form of p63 inhibits apoptosis in a p53-independent manner

Biochemical and Biophysical Research Communications

Volumn 344, Issue 1, 2006, Pages 166-172

  Lee, Hae ock ^a   Lee, Jung Hwa ^a   Choi, Eunhee ^a   Seol, Ja Young ^b   Yun, Yungdae ^b   Lee, Hyunsook ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

Np63 ; Apoptosis; DNA damage; p53; Tumorigenesis

Indexed keywords

PROTEIN P53; PROTEIN P63;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA DAMAGE; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE; STEM CELL; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELLS, CULTURED; DNA DAMAGE; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; MUTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33646046495     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.128     Document Type: Article

References (32)

1. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
2. Lee H., and Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev. Cell 2 (2002) 607-616
3. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R., and Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398 (1999) 708-713
4. Celli J., Duijf P., Hamel B.C., Bamshad M., Kramer B., Smits A.P., Newbury-Ecob R., Hennekam R.C., Van Buggenhout G., van Haeringen A., Woods C.G., van Essen A.J., de Waal R., Vriend G., Haber D.A., Yang A., McKeon F., Brunner H.G., and van Bokhoven H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99 (1999) 143-153
5. Koster M.I., Kim S., Mills A.A., DeMayo F.J., and Roop D.R. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18 (2004) 126-131
6. Keyes W.M., Wu Y., Vogel H., Guo X., Lowe S.W., and Mills A.A. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19 (2005) 1986-1999
7. Jacobs W.B., Govoni G., Ho D., Atwal J.K., Barnabe-Heider F., Keyes W.M., Mills A.A., Miller F.D., and Kaplan D.R. p63 is an essential proapoptotic protein during neural development. Neuron 48 (2005) 743-756
8. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., and McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 (1999) 714-718
9. Yamaguchi K., Wu L., Caballero O.L., Hibi K., Trink B., Resto V., Cairns P., Okami K., Koch W.M., Sidransky D., and Jen J. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int. J. Cancer 86 (2000) 684-689
10. Ratovitski E.A., Patturajan M., Hibi K., Trink B., Yamaguchi K., and Sidransky D. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proc. Natl. Acad. Sci. USA 98 (2001) 1817-1822
11. Parsa R., Yang A., McKeon F., and Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Invest. Dermatol. 113 (1999) 1099-1105
12. Park B.J., Lee S.J., Kim J.I., Lee C.H., Chang S.G., Park J.H., and Chi S.G. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60 (2000) 3370-3374
13. Wang T.Y., Chen B.F., Yang Y.C., Chen H., Wang Y., Cviko A., Quade B.J., Sun D., Yang A., McKeon F.D., and Crum C.P. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum. Pathol. 32 (2001) 479-486
14. Nishi H., Isaka K., Sagawa Y., Usuda S., Fujito A., Ito H., Senoo M., Kato H., and Takayama M. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int. J. Oncol. 15 (1999) 1149-1153
15. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
16. Moore J.E., McMullen C.B., Mahon G., and Adamis A.P. The corneal epithelial stem cell. DNA Cell Biol. 21 (2002) 443-451
17. Daniels J.T., Dart J.K., Tuft S.J., and Khaw P.T. Corneal stem cells in review. Wound Repair Regen. 9 (2001) 483-494
18. Yang A., Kaghad M., Caput D., and McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18 (2002) 90-95
19. Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I., Bondanza S., Ponzin D., McKeon F., and De Luca M. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. USA 98 (2001) 3156-3161
20. Radu E., Simionescu O., Regalia T., Dumitrescu D., and Popescu L.M. Stem cells (p63(+)) in keratinocyte cultures from human adult skin. J. Cell Mol. Med. 6 (2002) 593-598
21. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
22. Rieger K.M., Little A.F., Swart J.M., Kastrinakis W.V., Fitzgerald J.M., Hess D.T., Libertino J.A., and Summerhayes I.C. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer 72 (1995) 683-690
23. Caspari T. How to activate p53. Curr. Biol. 10 (2000) R315-R317
24. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072
25. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 10 (2003) 400-403
26. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
27. Stewart Z.A., Tang L.J., and Pietenpol J.A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20 (2001) 113-124
28. Liefer K.M., Koster M.I., Wang X.J., Yang A., McKeon F., and Roop D.R. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res. 60 (2000) 4016-4020
29. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
30. Brachmann R.K., Vidal M., and Boeke J.D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA 93 (1996) 4091-4095
31. Rocco J.W., Leong C.O., Kuperwasser N., DeYoung M.P., and Ellisen L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9 (2006) 45-56
32. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K., and Lane D.P. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19 (2005) 2122-2137